ARTL Key Statistics, Chart & Performance
The current stock price of ARTL is 1.78 USD. In the past month the price decreased by -47.18%. In the past year, price decreased by -71.75%.
ARTL Latest News, Press Relases and Analysis
ARTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.67 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.85 | 496.24B | ||
| MRK | MERCK & CO. INC. | 11.4 | 250.78B | ||
| PFE | PFIZER INC | 7.88 | 143.39B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.28 | 97.21B | ||
| ZTS | ZOETIS INC | 19.38 | 54.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.18B | ||
| VTRS | VIATRIS INC | 4.54 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.05 | 11.47B | ||
| CORT | CORCEPT THERAPEUTICS INC | 88.31 | 8.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.75B |
Related stock screener links
About ARTL
Company Profile
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Company Info
ARTELO BIOSCIENCES INC
505 Lomas Santa Fe, Suite 160
Solana Beach CALIFORNIA 92037 US
CEO: Gregory D. Gorgas
Employees: 5
Phone: 18589257049
ARTELO BIOSCIENCES INC / ARTL FAQ
What does ARTELO BIOSCIENCES INC do?
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
What is the stock price of ARTELO BIOSCIENCES INC today?
The current stock price of ARTL is 1.78 USD. The price increased by 6.59% in the last trading session.
Does ARTELO BIOSCIENCES INC pay dividends?
ARTL does not pay a dividend.
What is the ChartMill rating of ARTELO BIOSCIENCES INC stock?
ARTL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the market cap for ARTELO BIOSCIENCES INC?
ARTELO BIOSCIENCES INC (ARTL) has a market capitalization of 3.56M USD. This makes ARTL a Nano Cap stock.
Who owns ARTELO BIOSCIENCES INC?
You can find the ownership structure of ARTELO BIOSCIENCES INC (ARTL) on the Ownership tab.
ARTL Technical Analysis
ARTL Financial Highlights
Over the last trailing twelve months ARTL reported a non-GAAP Earnings per Share(EPS) of -20.92. The EPS decreased by -19.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -241.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARTL Forecast & Estimates
6 analysts have analysed ARTL and the average price target is 30.6 USD. This implies a price increase of 1619.1% is expected in the next year compared to the current price of 1.78.